

Zuerich, May 19<sup>th</sup> 2011

## **Roche purchases MCSGP equipment**

Today, Roche Diagnostics GmbH inked an agreement about the purchase of a MCSGP-unit from ChromaCon AG including a license agreement, which gives Roche undisclosed rights to use ChromaCon's patented MCSGP technology.

The target field of application for the MCSGP-technology at Roche is the continuous, chromatographic purification of therapeutic proteins and polypeptides, including molecular entities as monoclonal antibodies (mAb) and mAb fragments. The drivers for Roche to use the MCSGP-technology are its ability to strongly increase downstream processing (DSP) throughput, to reduce the buffer consumption as well as the DSP footprint and to increase the yields.

Dr. Guido Ströhlein, CEO of ChromaCon, comments: "After having built several MCSGP-units at various scales, we are particularly pleased to have Roche as an additional customer for ChromaCon's MCSGP-technology. As Roche is one of the major players in the biopharmaceutical industry, we look forward to support Roche to establish the MCSGP-technology as chromatographic purification platform for a variety of DSP challenges.

### ***About ChromaCon AG***

ChromaCon is a Swiss biopharmaceutical tool company providing enabling purification technologies, equipment and services. Its proprietary Contichrom<sup>™</sup> technology (using the MCSGP principle) is based on continuous chromatography, a powerful tool for the economic purification of components from complex mixtures, enabling the development of previously not accessible novel biological medicines and life cycle products with improved characteristics.

For more information, please contact  
ChromaCon AG, Technoparkstr. 1, CH- 8005 Zuerich  
Dr. Guido Ströhlein, CEO  
guido.stroehlein@chromacon.ch  
Tel. +41-44-445 20 10  
www.chromacon.ch